Clinical trials
Completed Phase 1/2 Leukemia, Myelogenous, Chronic, BCR-ABL Positive trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
49 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2001 | 2 |
| 2002 | 2 |
| 2004 | 6 |
| 2005 | 6 |
| 2006 | 4 |
| 2007 | 1 |
| 2008 | 5 |
| 2009 | 3 |
| 2010 | 2 |
| 2011 | 1 |
| 2012 | 7 |
| 2013 | 5 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2020 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 49 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| M.D. Anderson Cancer Center | 6 |
| Novartis Pharmaceuticals | 5 |
| Fred Hutchinson Cancer Center | 4 |
| National Cancer Institute (NCI) | 4 |
| Bristol-Myers Squibb | 3 |
| National Heart, Lung, and Blood Institute (NHLBI) | 2 |
| Accenture | 1 |
| Ariad Pharmaceuticals | 1 |
| Baylor College of Medicine | 1 |
| Cell Medica Ltd | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 49 |
| Leukemia, Myeloid, Acute | 25 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 24 |
| Myelodysplastic Syndromes | 22 |
| Leukemia | 15 |
| Lymphoma, Non-Hodgkin | 12 |
| Blast Crisis | 10 |
| Hodgkin Disease | 9 |
| Hematologic Neoplasms | 8 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 8 |
Trials
Showing 1 to 25 of 49. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.